Outcome of dose-escalated intensity-modulated radiotherapy for limited disease small cell lung cancer

Purpose: An optimal once-daily radiotherapy (RT) regimen is under investigation for definitive concurrent chemoradiotherapy (CCRT) in limited disease small cell lung cancer (LD-SCLC). We compared the efficacy and safety of dose escalation with intensity-modulated (IMRT).Materials Methods: Between January 2016 March 2021, patients treated CCRT LD-SCLC IMRT were retrospectively reviewed. Patients who received a total <50 Gy or those history thoracic RT surgery excluded. The divided into two groups (standard dose-escalated) based on biologically effective (BED, α/β = 10) 70 Gy. chemotherapeutic comprised four cycles etoposide cisplatin.Results: One hundred twenty-two analyzed median follow-up was 27.8 months (range, 4.4 to 76.9 months). age 63 years 35 78 years) majority had smoking (86.0%). 1- 3-year overall survival rates escalated group significantly higher than standard (93.5% 50.5% vs. 76.7% 33.3%, respectively; p 0.008), as freedom from in-field failure (91.4% 66.5% 73.8% 46.9%, 0.018). incidence grade 2 acute late pneumonitis not different between (p 0.062, 0.185). Conclusion: Dose-escalated led improved locoregional control survival, no increase toxicity.